ホーム › 肝臓がん（肝細胞がん） › テキサス
テキサスにおける肝臓がん（肝細胞がん）の臨床試験
テキサス内の拠点で、肝臓がん（肝細胞がん）に関する50件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A Study of ZW251 in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/05更新 · NCT07164313Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- 他2件
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06726161National Liver Cancer Screening Trial
- UT Southwestern Medical Center and Parkland Hospital, Dallas
- Baylor College of Medicine, Houston
被験者募集中第4相
18歳〜85歳 · 全性別 · 2026/09/25更新 · NCT06084234A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- The University of Texas Md Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06427941Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
- M D Anderson Cancer Center, Houston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/09/14更新 · NCT04380545Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
- St. David's Medical Center, Austin
被験者募集中観察研究
22歳以上 · 全性別 · 2026/09/11更新 · NCT06486454GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
- University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/10更新 · NCT04864054Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Amarillo
- Research Site, Austin
- Research Site, Houston
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06921785THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
被験者募集中早期第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07446257Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- START San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT06582017Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
- University of Texas Southwestern Medical Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07689175Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- START-San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/24更新 · NCT06084481FOG-001 in Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Research Site, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/13更新 · NCT06795022A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Texas Oncology - West Texas, Amarillo
- Texas Oncology, P.A., Dallas
- Texas Oncology Gulf Coast, Pearland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06910657A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Baylor Scott & White Research Institute, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- Baylor Scott & White Medical Center, Temple
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- 他8件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
- M D Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/16更新 · NCT05092373Multi-analyte Blood Test Clinical Trial
- South Texas Research Institute, Edinburg
- Texas Gastro Research, El Paso
- Impact Research Institute, Waco
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/10更新 · NCT05199259CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules
- University of Texas Southwestern Medical Center, Dallas
被験者募集中
18歳以上 · 全性別 · 2026/07/02更新 · NCT06184152A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Dallas
- Clinical Trial Site, Houston
- Clinical Trial Site, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/17更新 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
被験者募集中
18歳〜75歳 · 全性別 · 2026/06/17更新 · NCT05486572A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma
- The University of Texas M. D. Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/10更新 · NCT07116486A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1相
16歳以上 · 全性別 · 2026/06/02更新 · NCT07197554Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy
- M D Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/26更新 · NCT04982653High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies
- M D Anderson Cancer Center, Houston
被験者募集中
19歳以上 · 全性別 · 2026/05/22更新 · NCT05053555DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
- USA13-0, Anderson
- USA12-0, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/05/22更新 · NCT06953089A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
- Harold C. Simmons Comprehensive Cancer Center, Dallas
- University of Texas MD Anderson Cancer Center, Houston
- DHR Health Institute for Research and Development, McAllen
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/27更新 · NCT05440708Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
- M D Anderson Cancer Center, Houston
被験者募集中観察研究健康なボランティア歓迎
全年齢 · 全性別 · 2026/04/15更新 · NCT05143619A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
- MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/13更新 · NCT06362369Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Houston Methodist Hospital Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/02更新 · NCT05733598Evaluation of Resection Techniques for Pancreatic Tumors
- Methodist Dallas Medical Center, Dallas
被験者募集中観察研究
18歳以上 · 全性別 · 2026/03/20更新 · NCT05128890Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
- Oncology Consultants, Houston
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/03/16更新 · NCT07176650Ligufalimab and Cadonilimab in Advanced Liver Cancers
- University of Texas Southwestern Medical Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/27更新 · NCT06789848Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
- Baylor College of Medicine, Houston
被験者募集中第2相
0歳〜30歳 · 全性別 · 2026/02/24更新 · NCT04134559ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。